Table 1 Clinical characteristics of study subjects at base line and after 5 weeks of ω-3 PUFAs supplementation
From: Beneficial effects of omega-3 fatty acids in the proteome of high-density lipoprotein proteome
Basal situation | Post w-3 PUFAs supplementation | p Value | |
|---|---|---|---|
Body mass index, Kg/m 2 | 26.1 (24.0-28.0) | 26.3 (24.1-27.9) | 0.753 |
Waist circunference, cm | 95.0 (87.1-98.5) | 95.0 (87.0-101) | 0.785 |
Systolic blood pressure, mmHg | 134 (115–139) | 122 (107–129) | 0.042 |
Dyastolic blood pressure, mmHg | 78.0 (67.7-85.5) | 77.5 (67.7-81.7) | 0.109 |
Total cholesterol, mg/dL | 208 (186–232) | 214 (190–249) | 0.345 |
LDL cholesterol, mg/dL | 136 (104–170) | 144 (107–184) | 0.173 |
HDL cholesterol, mg/dL | 49.0 (41.0-61.5) | 49.0 (45.7-59.2) | 0.496 |
Non-HDL cholesterol, mg/dL | 155 (122–191) | 162 (122–205) | 0.528 |
Triglycerides, mg/dL | 92.5 (74.2-127) | 92.0 (77.2-111) | 0.500 |
Apo A-I, mg/dL | 143 (136–166) | 150 (146–162) | 0.893 |
Apo B, mg/dL | 111 (90.6-145) | 109 (86.8-139) | 0.116 |
Lp(a), mg/dL | 57.3 (16.3-59.1) | 35.5 (16.3-66.7) | 0.273 |
CRP, mg/L | 2.55 (1.47-4.45) | 3.45 (0.80-5.20) | 0.345 |
Creatinine, mg/dL | 0.86 (0.82-0.99) | 0.94 (0.74-1.04) | 0.686 |
Glucose, mg/dL | 87.5 (79.0-93.5) | 78.5 (71.2-92.0) | 0.043 |